Results 211 to 220 of about 48,421 (285)

Bridging innovation and access: integrating cardiac amyloidosis into health system strengthening in the Americas. [PDF]

Lancet Reg Health Am
Zavaleta-Monestel E, Mora-Jiménez J, Arguedas-Chacón S, Salas-Segura J.   +3 more
europepmc   +1 more source

Right Ventricular-Pulmonary Artery Coupling as a Prognostic Marker in Cardiac Amyloidosis: A Comprehensive Review. [PDF]

Life (Basel)
Tsiamis N, Afendoulis D, Tountas C, Toulgaridis F, Tsakirian F, Tsalamandris S, Drakopoulou M, Tsioufis K, Kitsiou A, Toutouzas K.   +9 more
europepmc   +1 more source

The Vagal Link: Autonomic Nervous System Dysfunction in Cardiac Amyloidosis. [PDF]

J Clin Med
Barocelli F, Canu E, Pasini N, Allegri I, D'Orsi A, Bettella A, Crocamo A, Gurgoglione FL, Torlai Triglia L, Russo F, Guidorossi A, Notarangelo MF, Gaibazzi N, Ruffini L, Niccoli G.   +14 more
europepmc   +1 more source

CMR-based assessment of long-term effects of tafamidis in patients with cardiac transthyretin amyloidosis

Alexandru Zlibut, Michael Bietenbeck, Nuriye Akyol, Volker Vehof, Redouane Bouras, Khuraman Isgandarova, Claudia Meier, Maria Theofanidou, Philipp Stalling, Ali Yılmaz   +9 more
openalex   +1 more source

Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial [PDF]

Karola Jering, Marianna Fontana, Olivier Lairez, Simone Longhi, Olga Azevedo, Caroline Morbach, Shaun Bender, Patrick Y. Jay, John Vest, Bernard E. Bulwer, Narayana Prasad, Scott D. Solomon, Hicham Skali   +12 more
openalex   +1 more source

Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis. [PDF]

J Arrhythm
Almakadma AH, Ibrahim R, Pham HN, Habib E, Mahmoud AK, Awad K, Bhakta MD, Yang EH, El Masry HZ, Ayoub C, Arsanjani R.   +10 more
europepmc   +1 more source

Diagnostic approach to cardiac amyloidosis.

, 2014
Hilman Zulkifli Amin, Shumpei Mori, Naoto Sasaki, Ken–ichi Hirata   +3 more
openalex   +1 more source

SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Özlek B, Tanik VO.
europepmc   +1 more source